enocitabine has been researched along with Communicable Diseases in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asou, N; Fujimoto, K; Hiraoka, A; Kobayashi, T; Kuriyama, K; Ohno, R; Saito, H; Tanimoto, M; Teshima, H; Yoshida, M | 1 |
1 trial(s) available for enocitabine and Communicable Diseases
| Article | Year |
|---|---|
No increase of leukemia relapse in newly diagnosed patients with acute myeloid leukemia who received granulocyte colony-stimulating factor for life-threatening infection during remission induction and consolidation therapy. Japan Adult Leukemia Study Grou
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Communicable Diseases; Cytarabine; Daunorubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Mercaptopurine; Prednisolone; Recombinant Proteins; Recurrence; Remission Induction; Survival Analysis; Time Factors; Vincristine | 1993 |